Indianapolis court backs patent for Lilly cancer drug Alimta
A federal court has upheld the patent that protects Eli Lilly and Co.'s lung-cancer treatment from generic competition until 2022.
Health Care & Insurance
Articles
Pence continues to seek repeal of medical device tax
A number of Indiana lawmakers – including both of the state’s U.S. senators – have advocated for the elimination of the tax, in part because the state is home to several key medical device manufacturers.
Obamacare sign-ups on track to hit 7 million, sources say
The 7 million target, thought to be out of reach by most experts, was in sight on a day that saw surging consumer interest as well as vexing computer glitches.
Deadline brings crush of Indiana health coverage applicants
The last-minute flood of applicants in Indiana mirrored national trends as people sought to at least start the process Monday.
Do double-digit Obamacare rate hikes mean the law has failed? No, but …
For now, at least, the year-to-year price increases of individual insurance under Obamacare look a lot like they did before Obamacare. That’s not a failure, but it’s not a success either.
IU Health suffers small decline in 2013 profit
Indiana University Health’s business deteriorated last year in nearly every area. But price hikes and a surge in outpatient visits to Indianapolis-area facilities mostly offset those problems.
Cancer treatment makes Endocyte premium takeover target
Now that Indiana-based Endocyte Inc.’s experimental cancer treatment is proving successful, the company may command a takeover bid at one of the industry’s highest premiums on record.
Would-be Lilly competitor’s inhaled insulin tied to lung concerns
Afrezza, a powdered insulin used through an inhaler, would be the MannKind Corp.’s first marketed product. The treatment would compete against Lilly’s Humalog. An FDA report tied the drug to a decline in lung function.
Obama says more than 6M signed up for health care
Like much else about Obama's health care law, the milestone comes with a caveat: The administration has yet to announce how many consumers actually closed the deal by paying their first month's premium.
Where do hospital profits go?
When patients at Indianapolis-area hospitals pay their bills, they're not just funding their own health care. They're contributing to the care of Hoosiers in the rest of the state, too, especially care provided by hospital-employed physicians.
CNO Financial casts out former Conseco demons
It was an exorcism of CNO’s legacy Conseco business recently that’s really put the proverbial color back in the faces of management and investors.
Feds grant extra time to enroll for Obamacare
People who've started applying for health insurance but aren't able to finish before the March 31 enrollment deadline will get extra time, the Obama administration announced Tuesday.
Youth tanning measure signed into law by Pence
Minors under 16 no longer can hop into a tanning bed at Indiana salons, even with parental supervision.
WellPoint sees double-digit rate rise for Obamacare in 2015
Two months before health insurers must submit rate proposals for 2015 to government regulators, WellPoint Inc. fired a surprising shot across their bow.
Medic! Early signal shows hospital profits plunged in 2013
Franciscan Alliance, always the first to report its year-end financial results, put out numbers that show a real decline in profit from operations of 58 percent.
WellPoint shares top $100 on bullish 5-year forecast
The health insurer predicted growth in government-funded health insurance programs would push revenue above $100 billion by 2018. That prompted investors to push WellPoint stock above $100 per share—an all-time high for the company.
Lilly CEO got 10-percent pay boost last year
Lilly CEO John Lechleiter was paid $11.2 million in salary, bonus, stock and perks last year, according to Lilly’s proxy statement filed Monday morning. That represented a 10-percent increase over his take in 2012.
Indiana braces for flood insurance subsidy changes
Thousands of Indiana homeowners who live in flood-prone neighborhoods are bracing for insurance premium increases, despite Congress' latest fix for the government's debt-saddled flood insurance program.
Endocyte stock doubles after key approval in Europe
The stock price of Endocyte Inc. skyrocketed by as much as 130 percent Friday morning after the drug company got a thumbs up in Europe to market its first drug and received a new round of favorable clinical trial results.
Lilly diabetes drug wins backing from EU regulator
Indianapolis-based Lilly is expected to garner $518 million in annual sales from Jardiance by 2019, according to the average of five analyst estimates compiled by Bloomberg.